Investigating a new vaccine for Rift Valley fever
Safety and immunogenicity of a novel Rift Valley fever candidate vaccine, RVax-1
This study is testing a new vaccine called RVax-1 to help protect people from Rift Valley fever, a serious illness that can affect both humans and animals, especially in sub-Saharan Africa, and it aims to make sure the vaccine is safe and effective with just one shot.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas Med Br Galveston NIH-funded |
| Lab location | 1 site (Galveston, United States) |
| Project ID | NIH-10786066 on NIH RePORTER |
What this research studies
This research focuses on developing a novel vaccine, RVax-1, to protect against Rift Valley fever (RVF), a serious viral disease that affects both animals and humans in sub-Saharan Africa and other regions. The vaccine aims to be safe and highly immunogenic, meaning it should effectively stimulate the immune system to fight the virus. The approach involves testing the vaccine in animal models to ensure it is safe for human use and can provide strong immunity with just one dose. By vaccinating humans, the research hopes to contribute to controlling RVF outbreaks and protecting public health.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals living in or traveling to areas where Rift Valley fever is endemic, particularly those who may come into contact with infected animals.
Not a fit: Patients who do not live in or travel to regions affected by Rift Valley fever may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a safe and effective vaccine that protects individuals from Rift Valley fever, potentially reducing disease outbreaks.
How similar studies have performed: Previous research has shown promise in developing vaccines for similar zoonotic diseases, indicating potential for success with this novel approach.
Where this research is happening
Galveston, United States
- University of Texas Med Br Galveston — Galveston, United States (Active)
Researchers
- Principal investigator: Ikegami, Tetsuro — University of Texas Med Br Galveston
- Study coordinator: Ikegami, Tetsuro
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.